Patents by Inventor Brad Sleebs

Brad Sleebs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIMALARIAL AGENTS
    Publication number: 20230139282
    Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 4, 2023
    Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research, MSD R&D (China) Co., Ltd.
    Inventors: Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, John A. McCauley, David B. Olsen, Brad Sleebs, Tony Triglia, Dongmei Zhan, Lianyun Zhao
  • ANTIMALARIAL AGENTS
    Publication number: 20230013692
    Abstract: The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: November 16, 2020
    Publication date: January 19, 2023
    Applicants: Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical Research
    Inventors: John A. McCauley, Manuel de Lera Ruiz, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Dongmei Zhan, Lianyun Zhao
  • ANTIMALARIAL AGENTS
    Publication number: 20220331321
    Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: July 21, 2020
    Publication date: October 20, 2022
    Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research, MSD R & D (China) Co. LTD.
    Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
  • Anxiolytic compounds
    Patent number: 10954231
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 23, 2021
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • ACTIVATORS OF HIV LATENCY
    Publication number: 20190330167
    Abstract: The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating HIV expression in latently infected cells. Further still, the invention relates to pharmaceutical compositions comprising the novel compounds in combination with anti-HIV therapy compounds and their use in treating HIV infection in both animals and humans. The invention further provides means for preparing the compounds.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 31, 2019
    Inventors: Brad SLEEBS, Damian Francis John PURCELL, Jonathan JACOBSON, Sharon LEWIN, William NGUYEN
  • Anxiolytic compounds
    Patent number: 10233181
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • STRUCTURE OF PLASMEPSIN V IN COMPLEX WITH AN INHIBITOR AND USES THEREOF
    Publication number: 20190065668
    Abstract: In one aspect, the present invention relates to the crystal structure of Plasmodium vivax plasmepsin V in complex with an inhibitor, and to methods of using the crystal structure and related structural information to identify, design and/or screen for inhibitors or redesign known inhibitors that interact with and/or modulate plasmepsin V activity. In another aspect, the present invention relates to a class of compounds based on the inhibitor useful in the treatment of malaria.
    Type: Application
    Filed: June 8, 2016
    Publication date: February 28, 2019
    Inventors: Justin BODDEY, Alan COWMAN, Peter CZABOTAR, Tony HODDER, Brad SLEEBS
  • Anxiolytic compounds
    Patent number: 9975892
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105524
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20180105523
    Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20170183347
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: January 4, 2017
    Publication date: June 29, 2017
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 9573945
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: February 21, 2017
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20150166534
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: June 18, 2015
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Small-molecules as therapeutics
    Patent number: 9023848
    Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 5, 2015
    Assignee: Bionomics Limited
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Damian Wojciech Grobelny, Sue O'Connor, Jonathan Bayldon Baell, Brad Sleebs, Ian Phillip Street
  • Anxiolytic compounds
    Patent number: 8906912
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: December 9, 2014
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL SMALL-MOLECULES AS THERAPEUTICS
    Publication number: 20140088104
    Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.
    Type: Application
    Filed: March 2, 2012
    Publication date: March 27, 2014
    Applicant: Bionomics Limited
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Damian Wojciech, Sue O'Connor, Jonathan Bayldon Baell, Brad Sleebs, Ian Phillip Street
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20140045839
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: September 18, 2013
    Publication date: February 13, 2014
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 8614212
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 24, 2013
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
  • Anxiolytic compounds
    Patent number: 8551990
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 8, 2013
    Assignee: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Philip Street, Nurul Quazi, Chinh Thien Bui
  • NOVEL ANXIOLYTIC COMPOUNDS
    Publication number: 20130012508
    Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Bionomics Limited
    Inventors: Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui